Skip to main content

Advertisement

SpringerLink
Log in

Locally advanced nasopharyngeal cancer

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

The Head and Neck Cancer Intergroup phase III clinical trial (Int 0099) for patients with locally advanced, squamous cell carcinomas (SCC) of the nasopharynx (or NPC) has been recently completed in the United States. The results of this study have defined the new standard of treatment for the group of patients studied. Patients with untreated, locally advanced stages III and IV NPC were randomized to a conven-tional course of radiation, or to radiation given concurrently with chemotherapy followed by three courses of combination chemotherapy. The 3-year progression-free survival (PFS) and overall survival (OS) were 24% versus 69% (P < 0.001) and 46% versus 76% (P < 0.001) for the control and experimental groups, respectively. Recent updates of these survival figures show that they have not changed appreciably. The considerable improvement in OS versus PFS for the patient group receiving radiation alone is accounted for primarily by re-treatment with concurrent radiation-chemo-therapy, combination chemotherapy, and isolated salvage neck dissections. Highly significant differences in local control (41% vs 14%) and distant metastases (35% vs 13%) were demonstrated in favor of the chemoradiation treatment arm. The median age for these patients was 51 years, with a 2:1 male to female ratio. Although many patients had a significant history of tobacco exposure with or without alcohol use or abuse, only 24% had keratinizing or well-differentiated squamous (World Health Organization [WHO] I) type tumors. Whether these results can be extrapolated to the more common Asian variety (WHO II and III) of advanced NPC must be addressed in future clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Fandi A, Altun M, Azli N, et al.: Nasopharyngeal cancer, epidemiology, staging and treatment. Semin Oncol 1994, 21:382–397.

    PubMed  CAS  Google Scholar 

  2. Ho JHC: An epidemiological and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1978, 4:183–197.

    Google Scholar 

  3. Lores AD, Dickson RI, Riding K, et al.: Cancer of the nasopharynx in British Columbia. Am J Clin Oncol 1986, 9:281–291.

    Article  Google Scholar 

  4. Hsu JL, Glaser SL: Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol 2000, 34:27–53. Updated review of status of Epstein-Barr virus and naso-pharyngeal carcinomas.

    Article  PubMed  CAS  Google Scholar 

  5. Al-Kourainy K, Crissman J, Ensley JF, et al.: Excellent response to cis-platinum-based chemotherapy in patients with recurrent or previously untreated advanced nasopharyngeal carcinoma. Am J Clin Oncol 1988, 1:427–430.

    Article  Google Scholar 

  6. Decker DA, Drelichman A, Crissman J, et al.: Chemo-therapy for nasopharyngeal carcinoma. A ten-year experience. Cancer 1983, 52:602–605.

    Article  PubMed  CAS  Google Scholar 

  7. Fandi A, Bachouchi M, Azli N, et al.: Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol 2000, 18:1324–1330.

    PubMed  CAS  Google Scholar 

  8. Teo PML, Kwan WH, Lee WY, et al.: Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma.Cancer 77:2423–2431.

  9. Pathmanathan R, Prasad U, Chandrika G, et al.:Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol 1995, 146:1355–1367.

    PubMed  CAS  Google Scholar 

  10. Neel HB, Pearson GR, Weiland LH, et al.: Application of Epstein-Barr virus serology to the diagnosis and staging of North American patients with naso-pharyngeal carcinoma. Otolaryngol Head Neck Surg 1983, 91:255–262.

    PubMed  Google Scholar 

  11. Yip TT, Lau WH, Chan JK, et al.: Prognostic significance of DNA flow cytometric analysis in patients with nasopharyngeal carcinoma. Cancer 1998, 83:2284–2292. Discussion of DNA content parameters and outcome in patients with nasopharyngeal carcinomas and other parameters.

    Article  PubMed  CAS  Google Scholar 

  12. Cheng DS, Campbell BH, Clowry LJ, et al.: DNA content in nasopharyngeal carcinoma. Am J Otolaryngol 1990, 11:393–397.

    Article  PubMed  CAS  Google Scholar 

  13. Costello F, Mason BR, Collins RJ, Kearsley JH:A clinical and flow cytometric analysis of patients with nasopharyngeal cancer. Cancer 1990, 66:1789–1795.

    Article  PubMed  CAS  Google Scholar 

  14. Sung NS, Zeng Y, Raab-Traub N: Alterations on chromosome 3 in endemic and nonendemic naso-pharyngeal carcinoma. Int J Cancer 2000, 86:244–250.

    Article  PubMed  CAS  Google Scholar 

  15. Huang DP, Lo KW, van Hasselt CA, et al.: A region of homozygous deletion on chromosome 9p21-22 in primary nasopharyngeal carcinoma. Cancer Res 1994, 54:4003–4006.

    PubMed  CAS  Google Scholar 

  16. Hui AB, Lo KW, Leung SF, et al.: Loss of heterozygosity on the long arm of chromosome 11 in nasopharyn-geal carcinoma. Cancer Res 1996, 56:3225–3229.

    PubMed  CAS  Google Scholar 

  17. Tsang YS, Lo KW, Leung SF, et al.: Two distinct regions of deletion on chromosome 13q in primary naso-pharyngeal carcinoma. Int J Cancer 1999, 83:305–308.

    Article  PubMed  CAS  Google Scholar 

  18. Mutirangura A, Pornthanakasem W, Sriuranpong V, et al.: Loss of heterozygosity on chromosome 14 in nasopharyngeal carcinoma. Int J Cancer 1998, 78:153–156.

    Article  PubMed  CAS  Google Scholar 

  19. Shibosawa E, Tsutsumi K, Koizuka I, et al.: Absence of nuclear p16 from Epstein-Barr virus-associated undifferentiated nasopharyngeal carcinomas. Laryngoscope 2000, 110:93–97.

    Article  PubMed  CAS  Google Scholar 

  20. Lo KW, Cheung ST, Leung SF, et al.: Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 1996, 56:2721–2725.

    PubMed  CAS  Google Scholar 

  21. Lo KW, Huang DP, Lau KM: p16 gene alterations in nasopharyngeal carcinoma. Cancer Res 1995, 2039–2043.

  22. Gulley ML, Nicholls JM, Schneider BG, et al.: Naso-pharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product. Am J Pathol 1998, 52:865–869.

    Google Scholar 

  23. Claudio PP, Howard CM, Fu Y, et al.: Mutations in the retinoblastoma-related gene RB2/p130 in primary nasopharyngeal carcinoma. Cancer Res 2000, 60:8–12.

    PubMed  CAS  Google Scholar 

  24. Lo KW, Mok CH, Huang DP, et al.: p53 mutation in human nasopharyngeal carcinomas. Anticancer Res 1992, 12:1957–1963.

    PubMed  CAS  Google Scholar 

  25. Chakrani F, Armand JP, Lenoir G, et al.: Mutations clustered in exon 5 of the p53 gene in primary nasopharyngeal carcinomas from Southeastern Asia. Int J Cancer 1995, 61:316–320.

    Article  PubMed  CAS  Google Scholar 

  26. Spruck CH, Tsai YC, Huang DP, et al.: Absence of p53 gene mutations in primary nasopharyngeal carcino-mas. Cancer Res 1992, 52:4787–4790.

    PubMed  CAS  Google Scholar 

  27. Van Tornout JM, Spruck CH, Shibata A, et al.:Presence of p53 mutations in primary nasopharyngeal carcinoma (NPC) in non-Asians of Los Angeles, California, a low-risk population for NPC. Cancer Epidemiol Biomarkers Prev 1997, 6:493–497.

    PubMed  Google Scholar 

  28. Masuda M, Shinokuma A, Hirakawa N, et al.: Expres-sion of bcl-2-, p53, and Ki-67 and outcome of patients with primary nasopharyngeal carcinomas following DNA-damaging treatment. Head Neck 1998, 20:640–644.

    Article  PubMed  CAS  Google Scholar 

  29. Sun Y, Hegamyer G, Colburn NH: Nasopharyngeal carcinoma shows no detectable retinoblastoma susceptibility gene alterations. Oncogene 1993, 8:791–795.

    PubMed  CAS  Google Scholar 

  30. Mutirangura A, Charuruks N, Shuangshoti S, et al.:Identification of distinct regions of allelic loss on chromosome 13q in nasopharyngeal cancer from paraffin embedded tissues. Int J Cancer 1999, 83:210–214.

    Article  PubMed  CAS  Google Scholar 

  31. Roychowdhury DF, Tseng AJ, Fu KK, et al.: New prog-nostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression. Cancer 1996, 77:1419–1426.

    Article  PubMed  CAS  Google Scholar 

  32. Porter MJ, Field JK, Leung SF, et al.: The detection of the c-myc and ras oncogenes in nasopharyngeal carcinoma by immunohistochemistry. Acta Otolaryngol 1994, 14:105–109.

    Google Scholar 

  33. Qian CN, Zhang CQ, Guo X, et al.: Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma. Cancer 2000, 88:255–261.

    Article  PubMed  CAS  Google Scholar 

  34. Wakisaka N, Wen QH, Yoshizaki T, et al.: Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in naso-pharyngeal carcinoma. Laryngoscope 1999, 109:810–814.

    Article  PubMed  CAS  Google Scholar 

  35. Vera-Sempere FJ, Burgos JS, Botella MS, Morera C:Immunohistochemical expression of Bcl-2 onco-protein in EBV-associated nasopharyngeal carcinoma correlated to histological type and survival. Histol Histopathol 1997, 12:9–18.

    PubMed  CAS  Google Scholar 

  36. Tsai ST, Jin YT, Leung HW, et al.: Bcl-2 and proliferating cell nuclear antigen (PCNA) expression correlates with subsequent local recurrence in nasopharyngeal carcinomas. Anticancer Res 1998, 18:2849–2854.

    PubMed  CAS  Google Scholar 

  37. Harn HJ, Hsieh HF, Ho LI, et al.: Apoptosis in naso-pharyngeal carcinoma as related to histopathological characteristics and clinical stage. Histopathology 1998, 33:117–122.

    Article  PubMed  CAS  Google Scholar 

  38. Cheng RY, Yuen PW, Nicholls JM, et al.: Telomerase activation in nasopharyngeal carcinomas. Br J Cancer 1998, 77:456–460.

    PubMed  CAS  Google Scholar 

  39. Chang JT, Liao CT, Jung SM, et al.: Telomerase activity is frequently found in metaplastic and malignant human nasopharyngeal tissues. Br J Cancer 2000, 82:1946–1951.

    Article  PubMed  CAS  Google Scholar 

  40. Huang SC: Nasopharyngeal cancer: a review of 1605 patients treated radically with cobalt 60. Int Radiat Oncol Biol Phys 1980, 6:401–407.

    CAS  Google Scholar 

  41. Huang SC, Lui LT, Lynn TC: Nasopharyngeal cancer: study III. A review of 1206 patients treated with combined modalities. Int J Radiat Oncol Biol Phys 1985, 11:1789–1793.

    PubMed  CAS  Google Scholar 

  42. Lee AWM, Poon YF, Foo W, et al.: Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976–1985: overall survival and patterns of failure. Int J Oncol Biol Phys 1992, 23:261–270.

    CAS  Google Scholar 

  43. Qin D, Hu Y, Yan J, et al.: Analysis of 1379 patients with nasopharyngeal carcinoma treated by radiation. Cancer 1988, 61:1117–1124.

    Article  PubMed  CAS  Google Scholar 

  44. Wang DC, Cai WM, Hu YH, Gu XZ: Long-term survival of 1035 cases of nasopharyngeal carcinoma. Cancer 1988, 61:2338–2341.

    Article  PubMed  CAS  Google Scholar 

  45. Zhang EP, Lian PG, Cai KL, et al.: Radiation therapy of nasopharyngeal carcinoma: prognostic factors based on a 10-year follow-up of 1302 patients. Int J Radiat Oncol Biol Phys 1989, 16:301–305.

    PubMed  CAS  Google Scholar 

  46. Hong S, Wu HG, Chie EK, et al.: Neoadjuvant chemo-therapy and radiation therapy compared with radiation therapy alone in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1999, 45:901–905.

    Article  PubMed  CAS  Google Scholar 

  47. Teo P, Ho JHC, Choy D, et al.: Adjunctive chemotherapy to radical radiation therapy in the treatment of advanced nasopharyngeal carcinoma. Int J Oncol Biol Phys 1987, 13:679–685.

    CAS  Google Scholar 

  48. Teo PML, Chan ATC, Lee WY, et al.: Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemo-therapy. Int J Oncol Biol Phys 1999, 43:261–271.

    Article  CAS  Google Scholar 

  49. Al-Sarraf M, LeBlanc M, Giri S, et al.: Superiority of chemo-radiotherapy vs radiotherapy in patients with locally advanced nasopharyngeal cancer. Preliminary results of Intergroup randomized study. J Clin Oncol 1998, 16:1–9. Detailed description of the H&N Intergroup Phase III Trial 0099 for advanced nasopharyngeal carcinomas.

    Google Scholar 

  50. Al-Sarraf M, LeBlanc M, Giri PG, et al.: Chemoradio-therapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998, 4:1310–1317.

    Google Scholar 

  51. Ali H, Al-Sarraf M: Chemotherapy in advanced nasopharyngeal cancer. Oncology 2000, 8:1123–1230. Very recent review and critique of the state of the art for treat-ing patients with advanced stage nasopharyngeal carcinomas in North America and Asia.

    Google Scholar 

  52. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated naso-pharyngeal carcinoma: a positive effect on pro-gression-free survival. International Nasopharynx Cancer Study Group. VUMCAI trial. Int J Radiat Oncol Biol Phys 1996, 35:463–469.

    Article  Google Scholar 

  53. Chan ATC, Teo PML, Leung TWT, et al.: A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Oncol Biol Phys 1995, 33:569–577.

    Article  CAS  Google Scholar 

  54. Chua DTT, Sham JST, Choy D, et al.: Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma Cancer 1998, 83:2270–2283.

    Article  PubMed  CAS  Google Scholar 

  55. Tan EH, Chua ET, Wee J, et al.: Concurrent chemo-radiotherapy followed by adjuvant chemotherapy in Asian patients with nasopharyngeal carcinoma: toxicities and preliminary results. Int J Oncol Biol Phys 1999, 45:597–601.

    Article  CAS  Google Scholar 

  56. Rossi A, Molinari R, Boracchi P, et al.: Adjuvant chemo-therapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol 1988, 6:1401–1410.

    PubMed  CAS  Google Scholar 

  57. Chan ATC, Tao PML, Ngran RRC, et al.: A phase III randomized trial comparing concurrent chemo-therapy-radiotherapy with radiotherapy alone in local-regionally advanced nasopharyngeal carcinoma. Proc Am Soc Clin Oncol 2000, 19:415a.

    Google Scholar 

  58. Al-Sarraf M, Pajak TF, Marcial VA, et al.: Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. RTOG Study. Cancer 1987, 59:259–265.

    Article  PubMed  CAS  Google Scholar 

  59. Forastiere AA: Taxoids in head and neck cancer: the American approach. Review. Acta Otorhinolaryngol Belg 1999, 53:253–257.

    PubMed  CAS  Google Scholar 

  60. Cardinali M, Jakus J, Robbins KC, et al.: P21WAF retards the growth of human squamous cell carcinomas in vivo. Eur J Cancer 1998, 34:211–218.

    CAS  Google Scholar 

  61. Massimo Cardinali F, Kratochvil J, Ensley JF, et al.:Functional characterization in vivo of mutant p53 molecules derived from squamous cell carcinomas of the head and neck. Mol Carcinog 1997, 18:78–88.

    Article  Google Scholar 

  62. Shibuya TY, Wei WZ, Zormeier M, et al.: Anti CD3/ CD28 MoAb coated suture enhances HNSCC patients immune response. Arch Otolaryngol Head Neck Surg 1999, 125:1229–1234.

    PubMed  CAS  Google Scholar 

  63. Shillitoe EJ, May M, Patel V, et al.: Genome-wide analysis of oral cancer—early results from the Cancer Genome Anatomy Project. Oral Oncol 2000, 36:8–16.

    Article  PubMed  CAS  Google Scholar 

  64. Clayman GL, Frank DK, Bruso PA, Goepfert H: Adeno-virus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 1999, 5:1715–1722.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Hematology-Oncology Division, Wayne State University, Barbara Ann Karmanos Cancer Institute, 48203, Detroit, MI, USA

    John F. Ensley MD

  2. Department of Radiation Oncology, Wayne State University, Barbara Ann Karmanos Cancer Institute, 48203, Detroit, MI, USA

    Emad Youssef MD & Harold Kim MD

  3. Department of Otolaryngology-Head and Neck Surgery, Wayne State University, Barbara Ann Karmanos Cancer Institute, 48203, Detroit, MI, USA

    George Yoo MD

Authors
  1. John F. Ensley MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emad Youssef MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Harold Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. George Yoo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ensley, J.F., Youssef, E., Kim, H. et al. Locally advanced nasopharyngeal cancer. Curr. Treat. Options in Oncol. 2, 15–23 (2001). https://doi.org/10.1007/s11864-001-0013-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-001-0013-9

Keywords

Search

Navigation